Litcius/Paper detail

Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial

Benjamin Diamond, Neha Korde, Alexander M. Lesokhin, Eric L. Smith, Urvi A. Shah, Sham Mailankody, Malin Hultcrantz, Hani Hassoun, Sydney X. Lu, Carlyn Tan, Even H Rustad, Francesco Maura, Kylee Maclachlan, Tim Peterson, Andriy Derkach, Sean M. Devlin, Heather Landau, Michael Scordo, David J. Chung, Gunjan L. Shah, Oscar Lahoud, Katie Thoren, Kazunori Murata, Lakshmi V. Ramanathan, Maria E. Arcila, Caleb Ho, Mikhail Roshal, Ahmet Doǧan, Sergio Giralt, Ola Landgren

2021The Lancet Haematology95 citationsDOI

Topics & Concepts

LenalidomideMedicineMultiple myelomaMinimal residual diseaseOncologyResidualInternal medicineSurgeryLeukemiaAlgorithmComputer scienceMultiple Myeloma Research and TreatmentsCancer Treatment and PharmacologyHistone Deacetylase Inhibitors Research